ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

China's National Medical Products Administration (NMPA) Clears Blood Clot Removal Platform

Innovative product platform for blood clot treatment approved in People's Republic of China

SALT LAKE CITY, UT, March 11, 2025 /24-7PressRelease/ -- The National Medical Products Administration (NMPA) in the People's Republic of China has cleared the Control Medical Technology 7 – 11F Mechanical Thrombectomy platform to remove blood clots from peripheral vessels. The Control Medical Thrombectomy platform is a foundation of a growing clot management medical device pipeline developed by VentiV Scientific

"This NMPA clearance in the People's Republic of China is a milestone in our ability to reach patients in one of the world's largest and most dynamic markets," said Dan Ryan, VentiV Scientific, Board of Directors, Salt Lake City, Utah USA. "Our partner Shanghai Easy-Flow MedTech did a great job attaining NMPA clearance and we look forward to working them to serve patients in the People's Republic of China."

"We are excited to introduce this innovative solution to the Chinese market," said Zhenghua Miao, Chairman and General Manager of Easy-Flow. "With the ongoing growth of the peripheral thrombectomy market in China, the differentiated design of the Control System will provide clinicians with a broader range of treatment options and greater flexibility in clinical applications, ultimately enhancing patient outcomes."

Blood clot removal (thrombectomy) is a common procedure. Coronary thrombectomy is associated with acute myocardial infarction (AMI), neurovascular thrombectomy is associated with acute ischemic stroke, and peripheral thrombectomy is associated with peripheral arterial disease (PAD), acute limb ischemia (ALI), critical limb ischemia (CLI), chronic total occlusion (CTO), deep vein thrombosis (DVT), pulmonary embolism (PE), and other peripheral vascular disease (PVD).

During most thrombectomy procedures, clinicians access the femoral artery or vein, track a catheter over a guidewire to the thrombus (blood clot), and then apply suction with a syringe, aspirator, and/or electromechanical pump. Blood clot age, size, and location plus catheter size, type, shape, and aspiration force are important variables during thrombectomy.

"Blood clots range from soft-fresh clots to hard-aged thrombus," commented Mr. Ryan. "Our Control 7 – 11F Mechanical Thrombectomy System includes large-lumen, flexible, and kink-resistant catheters w/dilators powered by our proprietary mechanical Aspirator, syringes, and/or electromechanical pumps to treat a wide range of blood clots."

The Control Medical Technology 7 – 11F Mechanical Thrombectomy System includes 7F (0.090") outer diameter (OD) to 11F (0.140") OD catheters with flexible dilators for improved tracking, crossing, and access in the peripheral vasculature. Catheters may be connected to the Aspirator, syringes, and/or electromechanical pumps for increased speed, force, volume, and control.

Control Medical Technology, Inc. dba VentiV Scientific is a private company that designs, develops, and commercializes novel medical devices www.VentiVScientific.com.

Shanghai Easy-Flow Medical Tech Co., Ltd is a medical device company dedicated to providing integrated, minimally invasive solutions for the treatment of vascular diseases.

Media contact: Alan Harris (954) 534-9345 aharris@ventivscientific.com

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.